Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Brentuximab Vedotin Versus GDP in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05180097Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Complete Response Rate at 52 months. Started Nov 2022; status: recruiting.
02
Drugs
pembrolizumabbrentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05180097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180097.